# Immunosuppression and COVID-19 Boosters

> **NCT05415267** · PHASE3 · RECRUITING · sponsor: **Kirby Institute** · enrollment: 320 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** diphtheria and tetanus toxoids (adsorbed) vaccine
- **BIOLOGICAL:** COVID-19 vaccine

## Key facts

- **NCT ID:** NCT05415267
- **Lead sponsor:** Kirby Institute
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-21
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 320 (ESTIMATED)
- **Last updated:** 2026-02-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05415267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05415267, "Immunosuppression and COVID-19 Boosters". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05415267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*